NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--Jan 10,
2013 - BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading
developer of adult stem cell technologies for neurodegenerative
diseases, announced that it has successfully completed a 12-week
repeat dose toxicity study with its NurOwn cells in mice. The
company believes that the positive data from the study will support
its efforts to obtain approval for a future repeat dose clinical
study in ALS patients. The study was conducted at Harlan Israel's
laboratories, according to GLP (Good Laboratory Practice) standards
of the FDA. The study protocol was approved by the Israeli Ministry
of Health.

“We believe that repeat dosing is the key to the long-term
clinical efficacy of NurOwn and we are anxious to begin testing in
ALS patients. Our proprietary cryopreservation protocol will enable
us to do so without having to perform repeat bone marrow
aspirations for each dose,” commented Dr. Adrian Harel,
BrainStorm's CEO.

In the study, the animals received up to three intramuscular
injections of NurOwn, produced from cryopreserved, or frozen, cells
at concentrations 50–100 times the currently administered
clinical trial dose. The treatment was well tolerated, and no
adverse clinical effects were observed. Analyses included cytokine
profile assays, clinical pathology, necropsy and macroscopic
examination, as well as histopathological examinations.

BrainStorm is currently launching a Phase IIa combined
treatment, dose-escalating trial of its NurOwn cell therapy
candidate in ALS patients at the Hadassah Medical Center in
Jerusalem. The company was recently fast-tracked by the Israeli
Ministry of Health after reporting positive safety data for 12
patients in a Phase I/II trial.

BrainStorm is planning to expand its ALS clinical development to
the United States in 2013, pending FDA approval. Towards that goal,
the Company has entered into a Memorandum of Understanding with the
University of Massachusetts Medical School and Massachusetts
General Hospital to begin ALS clinical trials at these
institutions.

About BrainStorm Cell Therapeutics,
Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company
engaged in the development of first-of-its-kind adult stem cell
therapies derived from autologous bone marrow cells for the
treatment of neurodegenerative diseases. The Company holds the
rights to develop and commercialize its NurOwn technology through
an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more
information, visit the company's website at
www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data
and information constitute "forward-looking statements" and involve
risks and uncertainties that could cause BrainStorm Cell
Therapeutics Inc.'s actual results to differ materially from those
stated or implied by such forward-looking statements. Terms and
phrases such as “may,” “should,”
“would,” “could,” “will,”
“expect,” “likely,” “believe,”
“plan,” “estimate,” “predict,”
“potential,”and similar terms and phrases are
intended to identify these forward-looking statements.The
potential risks and uncertainties include, without limitation,
risks associated with BrainStorm's limited operating history,
history of losses; minimal working capital, dependence on its
license to Ramot's technology; ability to adequately protect the
technology; dependence on key executives and on its scientific
consultants; ability to obtain required regulatory approvals; and
other factors detailed in BrainStorm's annual report on Form 10-K
and quarterly reports on Form 10-Q available athttp://www.sec.gov.These factors should be
considered carefully, and readers should not place undue reliance
on BrainStorm's forward-looking statements.The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.